{"id":"NCT00981214","sponsor":"Forest Laboratories","briefTitle":"Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency","officialTitle":"An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2006-09","completion":"2006-09","firstPosted":"2009-09-22","resultsPosted":"2014-04-04","lastUpdate":"2017-03-16"},"enrollment":19,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Exocrine Pancreatic Insufficiency"],"interventions":[{"type":"DRUG","name":"EUR-1008 (APT-1008)","otherNames":["ZENPEPÂ®","Pancrelipase"]}],"arms":[{"label":"EUR-1008 (APT-1008)","type":"EXPERIMENTAL"}],"summary":"This is an open-label study to evaluate the efficacy and safety of Aptalis' (formerly Eurand) pancreatic enzyme product (PEP) microtabs in pediatric participants under age 7 with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI).","primaryOutcome":{"measure":"Percentage of Participants Who Were Responders After 1 Week of Treatment With Study Medication","timeFrame":"Day 11","effectByArm":[{"arm":"EUR-1008 (APT-1008)","deltaMin":68.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":19},"commonTop":["Abdominal pain","Steatorrhoea","Pyrexia","Rhinorrhoea","Faeces discoloured"]}}